Why do some patients thrive after bladder-preserving chemoradiotherapy while others face devastating outcomes?
As urologic oncologists, we have cared for patients with muscle-invasive bladder cancer who achieved long-term disease control after bladder-preserving chemoradiotherapy. At the same time, we have also witnessed patients experience rapid progression, metastatic disease, and devastating clinical courses despite receiving apparently similar treatment.
Conventional clinical information—such as tumor stage, nodal status, histology, and lymphovascular invasion—could not fully explain this difference.
This contrast was the starting point of our study. We wanted to understand whether the biology already present in the tumor before treatment could distinguish patients who would achieve durable disease control from those at high risk of progression.
Building a high-quality clinical cohort took years
This study was not created from samples collected for a single experiment. Tumor specimens and clinical information were accumulated over many years from patients undergoing bladder-preserving chemoradiotherapy.
From the beginning, we recognized that technical variation could easily obscure clinically meaningful biological signals. We therefore placed particular emphasis on standardization.
Tumor samples were collected using a consistent procedure, processed under predefined conditions, and analyzed using the same sequencing platform and workflow. Maintaining this consistency over a prolonged period required discipline from everyone involved.
The study could not have been completed by the research team alone. Close collaboration with multiple departments within Osaka Medical and Pharmaceutical University was essential, particularly the Translational Research division responsible for specimen processing, preservation, and long-term management.
The quality of the final dataset reflects the commitment of the clinical, pathological, radiological, translational, and laboratory teams to follow the same procedures over many years. This institutional cooperation transformed a long-term clinical sample collection effort into a research resource capable of addressing a biologically and clinically important question.
What we found
We analyzed pretreatment tumor RNA sequencing data from 179 patients treated with cisplatin-based bladder-preserving chemoradiotherapy.
Our analyses identified a 26-gene ferroptosis suppressor signature, which we termed the FSS. Ferroptosis is an iron-dependent form of cell death driven by lipid peroxidation and is closely linked to oxidative stress generated by chemotherapy and radiotherapy.
Patients with FSS-high tumors had significantly shorter radiographic progression-free survival and overall survival after chemoradiotherapy. This association remained significant after adjustment for conventional clinical factors.
FSS-high tumors were also characterized by basal/squamous features, reduced intratumoral CD8-positive T-cell infiltration, and immune-excluded tumor ecosystems. Importantly, the FSS provided prognostic information beyond clinical characteristics, molecular subtype, and immune ecotype.
To investigate whether this clinical association had a functional basis, we studied chemoradiotherapy-resistant bladder cancer cells using RNA sequencing, lipidomics, genome-wide CRISPR/Cas9 screening, and pharmacological experiments.
Resistant cells exhibited ferroptosis-suppressive transcriptional and metabolic features. The CRISPR screen identified major ferroptosis regulators, including GPX4, SLC7A11, and NFE2L2, as functionally relevant dependencies. Pharmacological induction of ferroptosis restored radiosensitivity in one resistant model, and the effect was attenuated by the ferroptosis inhibitor ferrostatin-1.
Together, these findings suggest that ferroptosis suppression represents a biologically relevant resistance-associated state linking tumor-intrinsic stress resistance, lipid metabolism, the immune microenvironment, and adverse clinical outcomes.
What the study does—and does not—show
Our findings do not mean that all chemoradiotherapy-resistant bladder cancers depend on ferroptosis suppression. Indeed, another resistant cell model did not show the same ferroptosis-associated phenotype, highlighting the biological heterogeneity of treatment resistance.
The current study also does not establish the FSS as a clinically validated treatment-selection test. The cohort was retrospective, and external validation remains necessary. In addition, although the FSS was associated with outcomes after bladder-preserving chemoradiotherapy, we cannot yet determine whether it reflects sensitivity specifically to radiation, cisplatin, or their combination.
Therefore, the FSS should currently be regarded as a candidate prognostic and resistance-associated biomarker rather than an established predictive biomarker.
Our next goal: bringing the findings closer to clinical practice
RNA sequencing of carefully preserved research specimens is valuable for biological discovery, but routine clinical implementation requires a more practical and reproducible approach.
Our next objective is to validate these findings using formalin-fixed, paraffin-embedded specimens, which are routinely collected and stored in clinical practice. We aim to determine whether the ferroptosis-suppressive state can be measured reliably using a clinically applicable assay in independent patient cohorts.
The long-term goal of our team is to make it possible to estimate a patient’s risk before bladder-preserving treatment begins.
Such information would not replace clinical judgment or determine treatment automatically. Rather, it could complement conventional clinical factors and support more informed discussions regarding bladder preservation, treatment intensification, alternative therapies, and post-treatment surveillance.
Ultimately, we hope to translate the biological differences observed between patients with durable disease control and those with devastating progression into a clinically useful tool that supports individualized treatment decisions.
Suggested standfirst
Years of standardized specimen collection enabled us to investigate why patients receiving similar bladder-preserving chemoradiotherapy can experience profoundly different outcomes. By integrating clinical transcriptomics with immune profiling, lipidomics, CRISPR screening, and functional experiments, we identified ferroptosis suppression as a candidate resistance-associated and prognostic state in muscle-invasive bladder cancer.